DNB Asset Management AS Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

DNB Asset Management AS increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,268 shares of the biopharmaceutical company’s stock after acquiring an additional 6,805 shares during the period. DNB Asset Management AS’s holdings in Alnylam Pharmaceuticals were worth $15,626,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after purchasing an additional 268,313 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after buying an additional 75,936 shares during the last quarter. Orbis Allan Gray Ltd boosted its position in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares in the last quarter. Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $662,837,000. Finally, American Century Companies Inc. increased its holdings in Alnylam Pharmaceuticals by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock valued at $584,957,000 after acquiring an additional 33,411 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Pushkal Garg sold 2,242 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the sale, the executive vice president directly owned 24,848 shares in the company, valued at approximately $7,704,867.84. The trade was a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 6,958 shares of the stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $2,157,536.64. Following the transaction, the chief executive officer directly owned 85,662 shares in the company, valued at approximately $26,562,072.96. This represents a 7.51% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 36,578 shares of company stock valued at $12,416,105. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $332.92 on Friday. The company has a market cap of $44.15 billion, a P/E ratio of 194.69 and a beta of 0.35. The business has a fifty day simple moving average of $360.54 and a 200-day simple moving average of $418.95. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm’s quarterly revenue was up 84.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.65) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Morgan Stanley lowered their price target on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research report on Friday, January 30th. Barclays started coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 target price on the stock. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Royal Bank Of Canada reduced their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 20th. Finally, Freedom Capital upgraded Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.